In summary, the combined administration of SGLT2 inhibitors and finerenone (vs. SGLT2 inhibitors alone or finerenone alone) in patients receiving or not receiving RAAS blockade agents demonstrated a greater reduction in UACR levels among CKD patients and minimized the risk of hyperkalemia compared with the finerenone group alone. Here, SLC5A2 is linked to chronic kidney disease.